Related Resources for this page:
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Clinical Trials
- Cancer Biomarkers
- CLL
- DLBCL
- Gastric Cancer
- Receptor-Mediated Endocytosis
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- fNHL
- Future Directions
- Antibody-Drug conjugates
- HER Signaling
- Receptor-Mediated Endocytosis
- Anti-PDL1 (MPDL3280A)
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- Emerging therapeutic options
- Emerging therapeutic options
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- HER Signaling
- Emerging therapeutic options
- Emerging therapeutic options
- Emerging therapeutic options
- Current research in glycoengineering
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Non-Antibody Biologics
- Extrinsic pathway
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Targeted Small Molecules
- MAPK Signaling
- PI3K/Akt/mTOR Signaling
- MEK Inhibitor (GDC-0973)
- PI3K Inhibitor (GDC-0941)
- Glossary
- Apoptosis
- The Bcl-2 family
- Apoptotic pathways
- Reactivating apoptosis
- Resisting apoptosis
- Useful resources
- Emerging therapeutic options
- Emerging therapeutic options
- Emerging therapeutic options
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Slide decks and videos
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Multiple Myeloma
- Traditional Monoclonal Antibodies
- Angiogenic Signaling
- B-cell Surface Proteins
- HER Signaling
- Anti-PDL1 (MPDL3280A)
- Direct cell death
- Emerging therapeutic options
- The evolving CLL treatment landscape
- Emerging therapeutic options
- Emerging therapeutic options
- Inhibition of HER2 dimerization
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Glossary
- Slide decks and videos
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Antibody-Drug conjugates
Dysregulation of Apoptosis
Apoptosis (programmed cell death) is a key process in cancer development and progression.1,2 The ability of cancer cells to avoid apoptosis and continue to proliferate is one of the fundamental hallmarks of cancer and is a major target of cancer therapy development.2 Developing novel molecules that promote apoptosis by targeting both the intrinsic and extrinsic apoptotic pathways advances our understanding of the mechanisms behind tumor cell proliferation, which may also lead to the development of effective cancer therapies.
Apoptosis is triggered through 2 main signaling pathways1,3,4:
- The extrinsic pathway, which is activated in response to multiple external pro-apoptotic signals, including endogenous Apo2L/TRAIL and other pro-apoptotic receptor agonists (PARAs)
- The intrinsic pathway, which is activated by cellular developmental cues or as a result of severe cellular stress (eg, DNA damage)
Dysregulation of apoptosis
All cells have a finite life span, and cell death occurs mainly as a result of passive necrotic processes or due to an active process of programmed cell death, or apoptosis.5,6 Apoptosis plays an important role in both human embryonic development and adult tissue homeostasis.6 Apoptosis is the most common mechanism by which the body eliminates damaged or unneeded cells without local inflammation from leakage of cell contents.5,7
In normal cells, apoptosis is initiated in response to certain developmental cues, such as a decrease in the local concentration of a particular tissue morphogen or growth factor. Other stimuli include severe stress or damage to vital cellular components, which can be caused by ionizing radiation, heat shock, toxins, cell detachment from surrounding tissue, bacterial or viral infection, and/or oncogenic signaling.1,8
Please note: this video contains sound so please adjust volume
References:
- 1.
- Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430. PMID: 12189384
- 2.
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. PMID: 10647931
- 3.
- Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4:139-163. PMID: 15725726
- 4.
- Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178-194. PMID: 15890640
- 5.
- Bree RT, Stenson-Cox C, Grealy M, Byrnes L, Gorman AM, Samali A. Cellular longevity: role of apoptosis and replicative senescence. Biogerontology. 2002;3:195-206. PMID: 12232501
- 6.
- Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci. 2004;1028:150-156. PMID: 15650241
- 7.
- Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 2005;258:479-517. PMID: 16313474
- 8.
- Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov. 2008;7:1001-1012. PMID: 18989337